- $6.39m
- $4.58m
- $37.32m
- 40
- 58
- 30
- 38
Annual income statement for Biofrontera, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 18.8 | 24.1 | 28.7 | 34.1 | 37.3 |
| Cost of Revenue | |||||
| Gross Profit | 9.78 | 11.4 | 13.5 | 16.6 | 18.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 28.5 | 49.3 | 47.3 | 49.4 | 54.8 |
| Operating Profit | -9.61 | -25.2 | -18.6 | -15.3 | -17.5 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.9 | -37.7 | -0.608 | -20.1 | -17.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11 | -37.7 | -0.64 | -20.1 | -17.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11 | -37.7 | -0.64 | -20.1 | -17.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11 | -37.7 | -0.64 | -20.1 | -17.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -25.6 | -67.9 | -0.07 | -15.6 | -3.18 |